<DOC>
	<DOCNO>NCT00529399</DOCNO>
	<brief_summary>The purpose study determine whether treatment multiple injection GAD-Alum preserve body 's ( endogenous ) insulin production patient recently diagnose type 1 diabetes mellitus ( T1DM ) .</brief_summary>
	<brief_title>Effects Recombinant Human Glutamic Acid Decarboxylase Progression Type 1 Diabetes New Onset Subjects</brief_title>
	<detailed_description>Type 1 diabetes ( T1D ) autoimmune disease . This mean immune system ( part body help fight infection ) mistakenly attack destroys cell produce insulin ( islet cell find pancreas call islet cell ) . As cell destroy , body 's ability produce insulin decrease . Glutamic acid decarboxylase ( GAD ) one major autoantigens ( protein immune system react ) involve autoimmune process underlie T1DM . GAD-Alum Recombinant human ( rhGAD65 ) use antigen-specific immune modulator . Previous study show may slow prevent autoimmune destruction pancreatic islet cell introduce `` immune tolerance '' . By administer excess autoantigen , body may stop attack cell produce insulin . If immune system 's attack halt patient recent onset T1DM , residual insulin secretion may maintain . This may beneficial decrease acute long-term diabetic complication well improve glucose control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Age 3 45 year Insulin dependent type 1diabetes mellitus diagnose within previous 3 month Stimulated Cpeptide level great equal 0.2 pmol/ml measure mixed meal tolerance test ( MMTT ) conduct 3 week diagnosis diabetes Presence GAD65 antibody At least one month last immunization Willing comply intensive diabetes management If participant woman reproductive potential , must willing avoid pregnancy negative pregnancy test Willing forgo routine clinical immunization first 100 day initial study drug administration Immunodeficiency clinically significant chronic lymphopenia Active infection Positive PPD test result Pregnant lactating anticipate become pregnant 24 month follow first injection Ongoing use medication know influence glucose tolerance Require use systemic immunosuppressant ( ) Serologic evidence current past HIV , Hep B , Hep C infection History malignancy Ongoing use noninsulin pharmaceutical affect glycemic control Participation another clinical trial new chemical entity within past 3 month Complicating medical issue abnormal clinical laboratory result interfere study conduct cause increase risk include neurological , clinically significant blood count abnormality ( lymphopenia , leukopenia , thrombocytopenia ) History epilepsy , head trauma cerebrovascular accident clinical History alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>immune tolerance</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>antigen-specific tolerance</keyword>
	<keyword>vaccine induce tolerance</keyword>
	<keyword>Beta-cell function</keyword>
	<keyword>T-cells</keyword>
	<keyword>DPT-1</keyword>
	<keyword>treatment type 1 diabetes</keyword>
	<keyword>new onset type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>Type 1 diabetes TrialNet</keyword>
	<keyword>TrialNet</keyword>
</DOC>